Prognostic value of soluble ST2 and NT-proBNP in symptomatic patients with heart failure and reduced ejection fraction

9 May 2026 (08:00 - 12:45)

Organised by:

Sign in to view the resources

About the speaker

Doctor Argyrios Ntalianis

Alexandra University Hospital, Athens (Greece)

5 More presentations in this session

Presentation thumbnail

Predictive accuracy of the H2FPEF score in patients with and without lung disease

Doctor C. Wegner Wippel (New Haven, US)

Presentation thumbnail

Predictors of heart failure with reduced or mildly reduced ejection fraction development in hypertrophic cardiomyopathy: a single-centre study

Doctor H. Santos Moreira (Porto, PT)

Presentation thumbnail

Six-minute walk distance uncovers high-risk HFrEF patients despite guideline-based assessment

Doctor M. Chudy (Bratislava, SK)

Presentation thumbnail

Prognostic implications of abnormal right ventricular-pulmonary artery coupling assessed by three-dimensional echocardiography in heart failure with preserved ejection fraction

Doctor H. Seo (Seoul, KR)

Presentation thumbnail

Determinants of recurrent-event model performance in TOPCAT-Americas

Doctor B. Szabo-Soderberg (Stockholm, SE)

Access the full session

Session thumbnail

Progress in predicting prognosis in heart failure?

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026

You may be interested in

Congress Presentation

Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: a phenomics approach.

Congress Presentation

Clinical characteristics and long-term prognosis of patients with heart failure with reduced, mildly reduced, and preserved left ventricular ejection fraction secondary to Chagas cardiomyopathy

Webinar

Advanced heart failure therapy in HF patients with preserved and mildly reduced ejection fraction

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources